Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel.

Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, Castellani R, Lynch T, Shulkin B, Drobics M, Staudenherz A, Ladenstein R.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):234-241. doi: 10.1007/s00259-016-3516-0. Epub 2016 Sep 24.

2.

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.

Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, Oudoux A, Śliwińska A, Taborska K, Biassoni L, Yanik GA, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, Matthay KK, Park JR, Kreissman SG, Valteau-Couanet D, Boubaker A.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):292-305. doi: 10.1007/s00259-017-3829-7. Epub 2017 Sep 23.

3.

Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values.

Černý I, Prášek J, Kašpárková H.

Nuklearmedizin. 2016 Aug 5;55(4):151-7. doi: 10.3413/Nukmed-0743-15-05. Epub 2016 Apr 7.

PMID:
27054367
4.

Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M.

J Clin Oncol. 2013 Mar 1;31(7):944-51. doi: 10.1200/JCO.2012.45.8794. Epub 2013 Jan 22.

PMID:
23341514
5.

Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.

Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, Maris JM, Yanik G, Hawkins RA, Matthay KK.

Pediatr Blood Cancer. 2006 Dec;47(7):865-74.

6.

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.

Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, Wioland M, Gomez F.

Med Pediatr Oncol. 2000 Apr;34(4):237-41.

PMID:
10742058
7.

Clinical usefulness of iodine-123-MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey.

Hashimoto T, Koizumi K, Nishina T, Abe K.

Ann Nucl Med. 2003 Dec;17(8):633-40.

PMID:
14971604
8.

Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.

Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP, Garaventa A, Lanino E, De Bernardi B, Scopinaro G.

Q J Nucl Med. 1995 Dec;39(4 Suppl 1):21-4.

PMID:
9002744
9.

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, Pearson AD, Cohn SL.

Br J Cancer. 2010 Apr 27;102(9):1319-26. doi: 10.1038/sj.bjc.6605621. Review.

10.

[123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma].

Okuyama C, Ushijima Y, Sugihara H, Okitsu S, Maeda T.

Kaku Igaku. 1998 Nov;35(9):835-42. Japanese.

PMID:
9916399
11.

Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.

Zhang H, Huang R, Cheung NK, Guo H, Zanzonico PB, Thaler HT, Lewis JS, Blasberg RG.

Clin Cancer Res. 2014 Apr 15;20(8):2182-91. doi: 10.1158/1078-0432.CCR-13-1153. Epub 2014 Feb 26.

12.

The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.

Schmidt M, Simon T, Hero B, Schicha H, Berthold F.

Eur J Cancer. 2008 Jul;44(11):1552-8. doi: 10.1016/j.ejca.2008.03.013. Epub 2008 Apr 16.

PMID:
18424129
13.

Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma.

Gauguet JM, Pace-Emerson T, Grant FD, Shusterman S, DuBois SG, Frazier AL, Voss SD.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26601. Epub 2017 Apr 27.

PMID:
28449267
14.

MIBG in Neuroblastoma Diagnostic Imaging and Therapy.

Sharp SE, Trout AT, Weiss BD, Gelfand MJ.

Radiographics. 2016 Jan-Feb;36(1):258-78. doi: 10.1148/rg.2016150099. Review.

PMID:
26761540
15.

Evaluation of the SIOPEN semi-quantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma.

Radovic B, Artiko V, Sobic-Saranovic D, Trajkovic G, Markovic S, Vujic D, Obradovic V.

Neoplasma. 2015;62(3):449-55. doi: 10.4149/neo_2015_053.

PMID:
25866225
16.

Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma.

Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, Klein M.

AJR Am J Roentgenol. 2008 Apr;190(4):1085-90. doi: 10.2214/AJR.07.2107.

PMID:
18356459
17.

Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.

Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A, Cohn SL.

J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):13-8.

PMID:
10029806
18.

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma

Riaz S, Bashir H, Khan SJ, Qazi A.

Mol Imaging Radionucl Ther. 2018 Oct 9;27(3):121-125. doi: 10.4274/mirt.52533.

19.

Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.

Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK.

J Nucl Med. 2018 Mar;59(3):502-508. doi: 10.2967/jnumed.117.195883. Epub 2017 Sep 8.

20.

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK.

J Clin Oncol. 2003 Mar 15;21(6):1082-6.

PMID:
12637474

Supplemental Content

Support Center